ADMA Biologics (NASDAQ:ADMA) could be worth up to $16 per share in a buyout, according to Jefferies.
That note on the thinly-traded $190M market cap name had the stock up about 15% to $2.52 in a manner of minutes. At current pixel time, it's ahead 4.3% to $2.29.
ADMA at the start of September launched its COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary immunoassay that detects SARS-CoV-2 neutralizing antibodies in plasma.
https://seekingalpha.com/news/3618495-volatile-action-in-adma-biologics-jefferies-talks-takeout
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.